Ibrutinib Has Time-dependent On- and Off-target Effects on Plasma Biomarkers and Immune Cells in Chronic Lymphocytic Leukemia

Ibrutinib is a covalently binding inhibitor of the B-cell receptor signaling-mediator Bruton’s tyrosine kinase (BTK) with great efficacy in chronic lymphocytic leukemia (CLL). Common side effects like atrial fibrillation (AF), bleeding and infections might be caused by ibrutinib’s inhibition of othe...

Descripción completa

Detalles Bibliográficos
Autores principales: Mulder, Tom A., Peña-Pérez, Lucía, Berglöf, Anna, Meinke, Stephan, Estupiñán, H. Yesid, Heimersson, Kia, Zain, Rula, Månsson, Robert, Smith, C. I. Edvard, Palma, Marzia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078281/
https://www.ncbi.nlm.nih.gov/pubmed/33912812
http://dx.doi.org/10.1097/HS9.0000000000000564

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078281/
https://www.ncbi.nlm.nih.gov/pubmed/33912812
http://dx.doi.org/10.1097/HS9.0000000000000564

Ejemplares similares